Laura A. Williams - Jun 5, 2024 Form 4 Insider Report for ARDELYX, INC. (ARDX)

Role: Chief Medical Officer
Signature: /s/ Elizabeth Grammer, Attorney-in-Fact for Laura A. Williams
Stock symbol: ARDX
Transactions as of: Jun 5, 2024
Transactions value $: -$758,080
Form type: 4
Date filed: 6/7/2024, 06:29 PM
Previous filing: May 23, 2024
Next filing: Aug 22, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ARDX	Common Stock	Options Exercise	$275K	+100K	+27.24%	$2.75	467K	Jun 5, 2024	Direct
transaction	ARDX	Common Stock	Sale	-$321K	-45K	-9.63%	$7.12	422K	Jun 5, 2024	Direct	F1
transaction	ARDX	Common Stock	Sale	-$713K	-100K	-23.69%	$7.13	322K	Jun 5, 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ARDX	Stock Option (Right to Buy)	Options Exercise	$0	-100K	-28.49%	$0.00	251K	Jun 5, 2024	Common Stock	100K	$2.75	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction was executed in multiple trades in prices ranging from $7.11 to $7.145, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F2	The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 5, 2023, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.

Content

This transaction was executed in multiple trades in prices ranging from $7.11 to $7.145, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 5, 2023, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.